Irbesartan Vocate

Irbesartan, the active ingredient in Irbesartan Vocate, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy, primarily in adult populations. By selectively antagonizing angiotensin II type 1 receptors, it promotes vasodilation and decreases aldosterone secretion, contributing to its antihypertensive effect.

GNH USA supplies Irbesartan Vocate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and clinics worldwide, providing reliable sourcing and regulatory support for global healthcare providers.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers systolic and diastolic blood pressure, reducing cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Proteinuria in diabetic kidney disease: reduces urinary protein excretion, helping preserve renal function.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Upper respiratory tract infection: cold‑like symptoms. - Hyperkalemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may impair breathing. - Acute renal failure: sudden loss of kidney function. - Severe hyperkalemia: dangerously high potassium that can affect heart rhythm. - Hepatic injury: abnormal liver enzyme elevations or hepatitis.

Before initiating therapy, patients should be evaluated for renal function, electrolyte balance, and potential drug interactions.

- Monitor blood pressure: adjust dose if target levels are not achieved. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: especially in patients on potassium‑sparing agents. - Avoid use in severe hepatic impairment: limited data on safety. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Irbesartan may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with aliskiren in diabetic patients: increased risk of renal impairment. - Dual therapy with ACE inhibitors or other ARBs: heightened risk of hyperkalemia and renal dysfunction. - Potassium‑sparing diuretics (e.g., spironolactone): may cause severe hyperkalemia. - High‑dose NSAIDs: can precipitate acute kidney injury.

Moderate Interactions (Monitor Closely): - Thiazide or loop diuretics: may enhance hypotensive effect. - Lithium: increased lithium levels, risk of toxicity. - Cyclosporine or tacrolimus: may raise serum concentrations of both drugs.